Philadelphia Research Consortium Memorandum

This Philadelphia Research Consortium Memorandum ("PRC Memorandum") is being entered into and between members and friends of the Philadelphia Research Community (each a "Member") as designated on the signature block, effective upon date of each Member's signature.

Whereas, the Members wish to catalyze new research collaborations between the Philadelphia Research Community and for-profit research and development partners, including startups, small and mid-size biotech and large pharmaceutical companies ("Corporate Partners").

Whereas, the Members wish to foster long-term, proactive and meaningful relationships with Corporate Partners to bolster Philadelphia's research and development pipeline.

Whereas, the Members wish to take proactive steps to remove unnecessary administrative burdens that often times interfere with impactful academic-industry relationships.

Whereas, the Members wish to clarify the need for prenegotiated and unproductive contract negotiations between the Members and Corporate Partners with regards to entering into new research collaborations between and amongst the parties.

Now, Therefore, the Members agree as follows:

1. Corporate Partners having proprietary compounds, a need to test their compounds in vivo and/or in vitro assays, and a desire to fund research in the Member(s) laboratory, may elect to utilize the Collaborative Research Agreement ("CRA") template, as is, attached hereto as Exhibit A.

2. The Member(s) will use good faith efforts to make no modifications to the CRA, or any revisions, if only required on a limited case-by-case basis, to ensure the utilization of a single, uniform contract instrument to govern funded preclinical research collaborations between the Member(s) and Corporate Partners.

3. The Members wish to collaborate and foster fruitful relationships between and amongst the Members and Corporate Partners, as may be appropriate, to create a vibrant Philadelphia life sciences research community.

This Philadelphia Research Consortium Memorandum is not binding on the Members. Any rights or licenses are granted unilaterally by any Member. Any Member may terminate participation at any time.

The Villanova Institute of Anatomy & Biology

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

University of the Sciences

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Temple University - Of The Commonwealth System of Higher Education

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Cheyney University of Pennsylvania

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Lehigh University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Cynthia A. Moultrie, Executive Director of Finance & Admin.

The Pennsylvania State University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Lehigh University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Theo Jefferson University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Thomas Jefferson University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Lehigh University

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Ronald F. Pollizzi
Associate Director, Contracts
Research Administration

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Lankenau Institute for Medical Research

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Robert F. Margeot
President & CEO

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Children's Hospital of Philadelphia

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]

Children's Hospital of Philadelphia

By: [Signature]
Name: [Name]
Title: [Title]
Date: [Date]